the specificity of ca-19-9 as tumour marker was 97 % in patients without gastro-intestinal disease , but in those with liver cirrhosis or choledocholithiasis it was only 56 % and 44 % , respectively .
C0017178
gastro-intestinal disease
C0023890
liver cirrhosis